GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. GLP-1s and Obesity, BaroStim Neo Revisited

FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx

JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726

II. ATTR Cardiomyopathy

ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434

Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915

ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689

III. Clopidogrel vs ASA Years After PCI

Long-term Clopidogrel Has Advantages After Coronary Stenting

https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8

Stop DAPT Original Trial

STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013

Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009

IV. Statin Use

Statin Use Remains Low for At-Risk Patients

https://www.medscape.com/viewarticle/999043

Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]